Levofloxacin for the Management of Hospital-Acquired, Ventilator-Associated and Healthcare-Associated Pneumonia (Interview with Prof. Marin H. Kollef)
Question
| HAP, VAP, and HCAP – Definition and mechanisms |
| Q01 | Defining HAP, VAP, and HCAP |
| Q02 | Incidence of HAP, VAP, and HCAP |
| Q03 | Mechanisms involved in developing HAP |
| Q04 | The diagnostic features |
| Q05 | Diagnostic approach and treatment |
| Mortality/morbidity associated with HAP/ VAP |
| Q06 | Mortality and morbidity rates |
| Q07 | Factors affect the mortality/ morbidity |
| Etiologic factors associated with HAP, VAP, and HCAP |
| Q08 | Etiologic pathogens responsible for HAP, VAP, and HCAP |
| Q09 | Factors promoting antimicrobial resistance |
| Q10 | Microbiologic etiology for HAP, VAP, and HCAP |
| HAP/ VAP and medical costs |
| Q11 | Effect of HAP/VAP on medical costs |
| Antibiotic therapy for HAP, VAP, and HCAP |
| Q12 | Initial selection of antibiotic therapy |
| Q13 | Clinical outcomes |
| Q14 | The features of fluoloquinolones |
| Q15 | Combination therapy vs. monotherapy |
| Q16 | Dosing of antibiotics for HAP, VAP, and HCAP |
| Prevention and management of HAP, VAP, and HCAP |
| Q17 | Prevention of HAP, VAP, and HCAP |
| Q18 | Optimal management of HAP, VAP, and HCAP |
| References |
LATEST TOPICS
RELATED ARTICLES
